Schrödinger co-founds immunology biotech Tectora in licensing, collaboration deal with NEA and RA Capital

Schrödinger co-founded Tectora with NEA and RA Capital, signing a licensing and collaboration deal to advance immunology and inflammation drug programs.

Tectora closed a $55 million Series A led by NEA and RA Capital to fund development.

Schrödinger contributed two early-stage small-molecule assets, receiving equity plus potential milestones and royalties.

Tectora will use Schrödinger’s computational platform and drug discovery team to move the programs toward clinical candidates.